Growth Hormone Deficiency (GHD) - Pipeline Analysis and Market Forecasts to 2016

The GHD Therapeutics Market is Forecast to Grow Until 2016

Online PR News – 18-May-2010 – – The global Growth Hormone Deficiency (GHD) therapeutics market was worth $2.2 billion in 2009. The market is expected to grow by 13.4% during the next seven years to reach $5.4 billion by 2016. The GHD market has been well served by synthetic Growth Hormone (GH), GH regulators and GH secretagogues. The major marketed products for GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These are indicated for the treatment of GHD in adults and children and have an efficacy of about 80%, but are lacking in safety. The treatment of GHD in adults seems ineffective through these options. Companies are now focusing on adult GHD, which will enable them to reap revenues from this growing market. The primary focus would be to provide safer and more efficacious products with improved formulations to reduce the frequency of administration. LG Life Sciences, Altus Pharmaceuticals, Ambrx Inc., Novo Nordisk and Ipsen are believed to be working on the same method of meeting the unmet need in the market. The global GHD market is heading towards a phase of continuous growth as more products are expected to join the market by 2016.

For further details, please click or add the below link to your browser:

The level of competition in the GHD market is strong. The current pharmacological therapies involve the administration of GH for the aim of treating GHD both in adult and pediatric patients. However, these therapies seem to be less effective in adult patients. The biosimilars used to treat GHD include Genotropin, Humatrope, Nutropin, Saizen and Norditropin. These agents are either GH secretagogues, synthetic hGH or GH releasers. The current market is well served by the present treatment options available, but the effective treatment for adult patients seems to be under question. The pharmaceutical and biotechnology players seem to overlook this largely untapped market.

The current treatment options for GHD do not seem to influence patients or physicians. Most of the marketed products available for the treatment of GHD are dosed once daily, which causes inconvenience among patients. This has been cited as the major reason for patients’ non-compliance to therapy. Thus, there is an urgent need for therapies which can decrease the frequency of administration and at the same time possess increased safety as compared to currently market products.

For further details, please click or add the below link to your browser:

Though most of the marketed products are meant for GHD treatment in adults and children, their use in adult patients seem to be ineffective other than for increasing muscle strength, reducing fat mass and improving metabolic profiles, which could predispose to cardiovascular disease. The most common side effects observed with somatropin replacement are hand swelling and stiffness, joint and muscle ache and the development of insulin resistance. Their potential long-term side effects are irreversible or can sometimes be even fatal. Some studies have also reported a higher cancer risk with increased GH activity or Insulin-like Growth Factor-1 (IGF-1) levels, which render safety a primary concern for GHD treatment developers. This implies that a risk-to-benefit ration needs to be determined more precisely while treating patients with GHD. Due to these issues, most of the physicians are conservative towards somatropin hormone replacement therapy and exercise caution while administering somatropin as a treatment.

GlobalData, the industry analysis specialist’s new report, “Growth Hormone Deficiency (GHD) -Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global growth hormone deficiency market. The report identifies the key trends shaping and driving the global growth hormone deficiency market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global growth hormone deficiency sector.

For further details, please click or add the below link to your browser:

Visit our report store:

Contact Information
Rajesh Gunnam
Progressive House, Maidstone Road, Foots Cray, Sidcup
Kent London, DA14 5HZ